The wall of AG for biosimilars- Inhibiting the spread pointed out one after another Biosimilar Forum

株式会社薬事日報社から許諾を受けて、株式会社シーエムプラスが英語に翻訳しております。
オリジナルの正式言語は日本語であり、内容および解釈については日本語が優先されます。
With permission from Yakuji Nippo, Limited, CM Plus Corporation translated into English.
The original article is authored in Japanese, and the Japanese shall prevail in meaning in terms of content and interpretation.

The wall of AG for biosimilars- "Inhibiting the spread" pointed out one after another Biosimilar Forum
October 16th, 2020

The spread of biosimilars has become a significant issue as the next target after achieving a generic product usage rate of 80%. At the "Biosimilar Forum" held on the web by the Biosimilar Council on the 14th, symposiasts pointed out that the authorized generic (AG) of biosimilars that appeared last year hindered the spread of biosimilars. However, opinions were calling for a review of medical fees, including introducing incentives to promote use.

(Continue to the next)

For this translated article in English, CM Plus Corporation shall have the copyright. Unauthorized reproduction of posted articles, photos, diagrams, etc. is prohibited.
Copyright © 2020 LSMIP office / CM Plus Singapore Pte. Ltd.